eli lilly phase 3 trial retatrutide said Thursday its experimental obesity drug delivered up to 28.3 percent body-weight reduction over 80 weeks in the pivotal TRIUMPH-1 trial, a result nearing the weight-loss range Lilly's triple agonist, retatrutide, delivered

We discussed my previous weight loss attempts, current health, medications, eating habits, physical activity, symptoms, and exactly what I had purchased online

The strongest results came with higher doses taken consistently

Nutritional Deficiencies: Losing weight too quickly may lead to inadequate nutrient intake, which can result in deficiencies

For the background on what Retatrutide is, how its triple-receptor mechanism differs from single and dual agonists, and what the research reports, read the full Retatrutide guide

The future of weight loss therapy is shifting toward more personalized and metabolically targeted care